Use of ampicilin plus ranitidine for Helicobacter pylori gastritis
Braz. j. med. biol. res
; 24(6): 567-72, 1991. tab
Article
en En
| LILACS
| ID: lil-99490
Biblioteca responsable:
BR26.1
RESUMO
Helicobacter pylori (formerly Campylobacter pylori) is now recognized as an etiological factor in gastritis and duodenal ulcers and probably also gastric ulcers. Eradication of the bacteria is fundamental to avoid ulcer relapse. Although bismuth salts have been shown to be effective for treatment, they are not commercially available in Brazil. We report an attempt to treat patients with Helicobacter pylori-associated gastritis with ampicilin (1000 mg twice daily for one month) and compare the results with the conventional treatment used in Brazil (ranitidine, 300 mg daily for one month) and with a combination of the two drugs. We studied 44 patients with histologically confirmed gastritis and with Helicobacter pylori, who were examined at the beginning and after one month of treatment. Ampicilin associated with ranitidine was better than ampicilin or ranitidine alone for the treatment of gastritis. Although ampicilin may be more efficient in patients with lower acid output we did not find a statistically significant difference between these two groups (ampicilin vs drug combination), perhaps owing to the small number of patients studied. When ampicilin was with ranitidine there was 25% normalization of the histological picture of the gastric mucosa. We conclude that ampicilin in combination with ranitidine may be a useful treatment for Helicobacter pylori-associated gastritis
Buscar en Google
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Ranitidina
/
Helicobacter pylori
/
Infecciones por Helicobacter
/
Gastritis
/
Ampicilina
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Revista:
Braz. j. med. biol. res
Asunto de la revista:
BIOLOGIA
/
MEDICINA
Año:
1991
Tipo del documento:
Article
Pais de publicación:
Brasil